SB 061

Drug Profile

SB 061

Alternative Names: SB-061

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SYMIC Biomedical
  • Developer Symic Bio
  • Class Proteoglycans
  • Mechanism of Action Cartilage replacements; Proteoglycan replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 07 Feb 2018 Top-line efficacy and adverse events data from the phase II MODIFY2 trial in Osteoarthritis released by Symic Bio
  • 07 Feb 2018 Symic Bio completes the phase II MODIFY2 trial in Osteoarthritis in Estonia (Intra-articular) (NCT03231280)
  • 23 Aug 2017 Symic Bio plans the phase IIb MODIFY-MRI trial in Osteoarthritis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top